[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Bianchini L, Maire G, Pedeutour F, Groupe Francophone de Cytogénétique Oncologique: [From cytogenetics to cytogenomics of dermatofibrosarcoma protuberans family of tumors]. Bull Cancer; 2007 Feb;94(2):179-89
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [From cytogenetics to cytogenomics of dermatofibrosarcoma protuberans family of tumors].
  • [Transliterated title] De la cytogénétique à la cytogénomique du dermatofibrosarcome de Darier-Ferrand (dermatofibrosarcoma protuberans) et des tumeurs apparentées.
  • Dermatofibrosarcoma protuberans (DP) is a rare, slow growing dermal neoplasm of intermediate malignancy.
  • It is made of spindle-shaped tumor cells in a storiform pattern often positive for CD34.
  • These chromosomal rearrangements lead to the formation of a specific fusion gene : COL1A1-PDGFB detected in rings as well as in translocations.
  • DP is therefore a unique example of tumor in which the same molecular event occurs either on rings or linear translocation derivatives and the chromosomal abnormalities display an age-related pattern.
  • So far, the COL1A1-PDGFB fusion gene remains the only fusion gene identified in this tumor.
  • It is also present in variant forms of DP such as giant cell fibroblastoma, Bednar tumor, adult superficial fibrosarcoma and the granular cell variant of DP demonstrating that these tumors are not distinct entities but morphological variants of DP.
  • [MeSH-major] Chromosomes, Human, Pair 17 / genetics. Chromosomes, Human, Pair 22 / genetics. Dermatofibrosarcoma / genetics. Oncogene Proteins, Fusion / genetics. Ring Chromosomes. Skin Neoplasms / genetics

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17337387.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / COLIA1-PDGFB fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


2. Bednar F, Simeone DM: Pancreatic cancer stem cells and relevance to cancer treatments. J Cell Biochem; 2009 May 1;107(1):40-5
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent evidence supports the existence of human pancreatic cancer stem cells, which appear to drive tumor initiation and progression and are particularly resistant to cell death induced by radiation or chemotherapy.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19301275.001).
  • [ISSN] 1097-4644
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 36
  •  go-up   go-down


3. Zhang GJ, Chen TB, Bednar B, Connolly BM, Hargreaves R, Sur C, Williams DL: Optical imaging of tumor cells in hollow fibers: evaluation of the antitumor activities of anticancer drugs and target validation. Neoplasia; 2007 Aug;9(8):652-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optical imaging of tumor cells in hollow fibers: evaluation of the antitumor activities of anticancer drugs and target validation.
  • The in vivo hollow fiber assay, in which semipermeable hollow fibers filled with tumor cells, are implanted into animals, was originally developed to screen for anticancer compounds before assessment in more complex tumor models.
  • To demonstrate that tumor cells inside hollow fibers can communicate with the host mice, we have used fluorescence imaging in vivo and CD31 immunostaining ex vivo to show that angiogenesis occurs around cell-filled hollow fibers by 2 weeks after subcutaneous implantation.
  • Bioluminescence imaging has been used to follow the number of luciferase-expressing tumor cells within implanted hollow fibers; proliferation of those cells was found to be significantly inhibited by docetaxel or irinotecan.
  • We also used bioluminescence imaging of hollow fibers to monitor the nuclear factor kappaB (NFkappaB) pathway in vivo; NFkappaB activation by lipopolysaccharide and tumor necrosis factor-alpha was evaluated in tumor cell lines genetically engineered to express luciferase controlled by an NFkappaB-responsive element.
  • These results demonstrate that optical imaging of hollow fibers containing reporter tumor cells can be used for the rapid and accurate evaluation of antitumor activities of anticancer drugs and for measurement of molecular pathways.
  • [MeSH-minor] Animals. Humans. Mice. Mice, Nude. Neoplasm Transplantation / instrumentation. Neoplasm Transplantation / methods. Optics and Photonics. Rats. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1999 Nov-Dec;19(6B):5423-8 [10697572.001]
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2A):903-11 [10810375.001]
  • [Cites] Anticancer Res. 2001 Mar-Apr;21(2A):869-72 [11396177.001]
  • [Cites] Mol Cancer Ther. 2002 Jun;1(8):629-37 [12479223.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16551-5 [12475931.001]
  • [Cites] Semin Cancer Biol. 2003 Apr;13(2):159-67 [12654259.001]
  • [Cites] Cancer Biol Ther. 2003 Mar-Apr;2(2):196-202 [12750563.001]
  • [Cites] Biotechniques. 2003 Jun;34(6):1184-8 [12813886.001]
  • [Cites] Nat Med. 2003 Jul;9(7):969-73 [12819780.001]
  • [Cites] Nat Med. 2004 Jun;10(6):643-8 [15122251.001]
  • [Cites] Mutat Res. 2004 Jul 13;551(1-2):199-211 [15225593.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6677-85 [15475458.001]
  • [Cites] Life Sci. 1995;57(2):131-41 [7603295.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):671-7 [9284815.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5263-6 [9850044.001]
  • [Cites] Br J Cancer. 1999 Oct;81(3):440-8 [10507768.001]
  • [Cites] Nat Med. 2004 Nov;10(11):1257-60 [15502845.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):971-81 [15709162.001]
  • [Cites] Mol Imaging. 2005 Jul-Sep;4(3):182-93 [16194450.001]
  • [Cites] Nat Rev Immunol. 2005 Oct;5(10):749-59 [16175180.001]
  • [Cites] Mol Cancer Ther. 2005 Oct;4(10):1495-504 [16227398.001]
  • [Cites] Methods Enzymol. 2005;399:530-49 [16338380.001]
  • [Cites] Int J Oncol. 2007 Jan;30(1):45-54 [17143511.001]
  • (PMID = 17786184.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Validation Studies
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC1950435
  • [Keywords] NOTNLM ; NFκB / Optical imaging / angiogenesis / bioluminescence imaging / hollow fiber
  •  go-up   go-down


Advertisement
4. Govaert GA, Plaisier PW: [Diagnostic image (237). A man with a swelling on his left buttock. Bednar tumor]. Ned Tijdschr Geneeskd; 2005 Apr 30;149(18):983
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic image (237). A man with a swelling on his left buttock. Bednar tumor].
  • A 42-year-old man was referred because of a pigmented dermatofibrosarcoma protuberans, a so-called Bednar tumour, on his left buttock.
  • [MeSH-major] Dermatofibrosarcoma / diagnosis. Skin Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15903039.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


5. Quigley EA, Marghoob AA, Busam KJ, Chen CS: A firm red-brown plaque on the arm. Dermatofibrosarcoma protuberans(DFSP), pigmented variant (Bednar tumor. Arch Dermatol; 2009 May;145(5):589-94
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A firm red-brown plaque on the arm. Dermatofibrosarcoma protuberans(DFSP), pigmented variant (Bednar tumor.
  • [MeSH-major] Dermatofibrosarcoma / pathology. Dermis / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Antigens, CD34 / metabolism. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Biopsy. Cell Proliferation. Diagnosis, Differential. Female. Humans. MART-1 Antigen. Melanoma / diagnosis. Middle Aged. Mohs Surgery. Neoplasm Proteins / metabolism. S100 Proteins / metabolism

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19451510.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Neoplasm Proteins; 0 / S100 Proteins
  •  go-up   go-down


6. Craver R, Dewenter T, Ebran N, Pedeutour F: COL1A1-PDGFB fusion in a pediatric Bednar tumor with 2 copies of a der(22)t(17;22). Cancer Genet Cytogenet; 2006 Jul 15;168(2):155-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] COL1A1-PDGFB fusion in a pediatric Bednar tumor with 2 copies of a der(22)t(17;22).
  • We present a 10-year-old girl with a pure Bednar tumor (pigmented dermatofibrosarcoma protuberans) of the right shoulder.
  • Cytogenetic analysis demonstrated 47 chromosomes with 2 copies of a derivative chromosome 22, der(22)t(17;22)(q22;q13).
  • This pure pediatric Bednar tumor in a child, like childhood dermatofibrosarcoma protuberans, had a linear structural abnormality rather than a ring chromosome that is more commonly encountered in adult Bednar and dermatofibrosarcoma protuberans tumors.
  • The underlying molecular abnormality in this pediatric Bednar tumor is the same as in dermatofibrosarcoma protuberans.
  • [MeSH-major] Chromosomes, Human, Pair 17 / genetics. Chromosomes, Human, Pair 22 / genetics. Dermatofibrosarcoma / genetics. Oncogene Proteins, Fusion / genetics. Translocation, Genetic / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16843106.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / COLIA1-PDGFB fusion protein, human; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


7. Ansari NA: Bednar tumor. Saudi Med J; 2005 Jun;26(6):1033
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bednar tumor.
  • [MeSH-major] Dermatofibrosarcoma / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Saudi Med J. 2004 Dec;25(12):2016-7 [15711690.001]
  • (PMID = 15983708.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


8. Wang J, Yang W: Pigmented dermatofibrosarcoma protuberans with prominent meningothelial-like whorls. J Cutan Pathol; 2008 Oct;35 Suppl 1:65-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pigmented dermatofibrosarcoma protuberans with prominent meningothelial-like whorls.
  • Dermatofibrosarcoma protuberans (DFSP) is a locally aggressive skin tumor.
  • In addition to the conventional type, several morphologic variants have been described.
  • Recognition of these uncommon variants will facilitate the diagnosis.
  • We report herein a peculiar case of pigmented DFSP (Bednar tumor) with prominent meningothelial-like whorls, a distinctive pattern that has not been described previously in DFSP.
  • The tumor occurred in a 40-year-old man who presented with a slowly growing mass on his left shoulder.
  • The overall histological features were consistent with Bednar tumor.
  • However, unexpected numerous meningothelial-like whorls were found in some areas of the tumor.
  • Like the tumor cells in typical areas of Bednar tumor these meningothelial-like whorls were also positive for CD34 but negative for epithelial membrane antigen and S100 protein.
  • The meningothelial-like whorls in Bednar tumor represent an eccentric arrangement of the tumor cells.
  • We propose the term 'pigmented DFSP with prominent meningothelial-like whorls' to highlight the distinctive pattern of this novel DFSP variant.
  • [MeSH-major] Dermatofibrosarcoma / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Blackwell Munksgaard 2008.
  • (PMID = 18544057.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


9. Kabumoto T, Fujiwara H, Kariya N, Tsujimoto T, Ito K, Ito M, Kobayashi H: Skin metastasis of dermatofibrosarcoma protuberans with distinct morphological features, confirmed by COL1A1-PDGFB fusion gene analysis. J Am Acad Dermatol; 2009 Jul;61(1):130-2
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin metastasis of dermatofibrosarcoma protuberans with distinct morphological features, confirmed by COL1A1-PDGFB fusion gene analysis.
  • We discuss a metastatic dermatofibrosarcoma protuberans on the occiput of a 53-year-old man whose initial tumor appeared on his forehead 23 years previously.
  • The pathology of the tumor that recurred at the initial site was fibrosarcomatous dermatofibrosarcoma protuberans, whereas the metastatic tumor was a pigmented dermatofibrosarcoma protuberans, the so-called Bednar tumor.
  • Because both tumors possessed the identical chimeric COL1A1-PDGFB fusion gene, the metastatic nature of the occipital tumor was confirmed.
  • [MeSH-major] Collagen Type I / genetics. Dermatofibrosarcoma / pathology. Head and Neck Neoplasms / pathology. Oncogene Proteins, Fusion / genetics. Proto-Oncogene Proteins c-sis / genetics. Skin Neoplasms / secondary

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19539850.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Collagen Type I; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins c-sis; 0 / collagen type I, alpha 1 chain
  •  go-up   go-down


10. Drut R: Polypoid dermal dendrocytic hamartoma in a giant congenital melanocytic nevus. Int J Surg Pathol; 2007 Jan;15(1):73-6
Genetic Alliance. consumer health - Nevus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Giant congenital melanocytic nevus (CMN) might be complicated by the development of several tumor types, mainly melanoma and rhabdomyosarcoma, but also poorly differentiated neoplasms.
  • The present report describes what appears to be a unique example of dermal hamartomatous polypoid CD34(+) fibrogenic proliferation devoid of melanin, namely a dendrocytoma, surrounded by the melanocytes from the nevus, located in the skin of the scrotum against a background of giant CMN.
  • The differential diagnosis included dermatofibrosarcoma protuberans, giant-cell fibroblastoma, angiofibroma, Bednar tumor, other types of dermal dendrocytic hamartoma, and neurocristic cutaneous hamartoma.
  • [MeSH-major] Hamartoma / complications. Hamartoma / pathology. Nevus, Pigmented / complications. Nevus, Pigmented / pathology. Scrotum / pathology
  • [MeSH-minor] Antigens, CD34. Humans. Immunohistochemistry. Infant. Male. Skin Diseases / complications. Skin Diseases / pathology. Skin Neoplasms / complications. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17172504.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


11. McAllister JC, Recht B, Hoffman TE, Sundram UN: CD34+ pigmented fibrous proliferations: the morphologic overlap between pigmented dermatofibromas and Bednar tumors. Am J Dermatopathol; 2008 Oct;30(5):484-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD34+ pigmented fibrous proliferations: the morphologic overlap between pigmented dermatofibromas and Bednar tumors.
  • Pigmented dermatofibrosarcoma protuberans (DFSP; Bednar tumor) constitutes 5%-10% of all cases of DFSP and shows morphologic features that overlap with melanocytic and fibrous proliferations.
  • We report 2 unusual cases of pigmented fibrous proliferations that demonstrate features of dermatofibromas and DFSP.
  • The first case is that of a 19-year-old man with a 3-year history of a slowly growing pigmented lesion on the right arm.
  • On clinical exam, the lesion was a 7-mm firm pigmented papulonodular lesion.
  • The second case is that of a 31-year-old woman with a 4- to 5-year history of a slowly enlarging, asymptomatic "dark area" on the right buttock.
  • On clinical exam, the lesion was a 2-cm darkly pigmented flat nodule.
  • Morphologically, both lesions are primarily dermal proliferations of spindled cells admixed with pigmented dendritic melanocytes.
  • Although overlap between standard dermatofibromas and DFSP is well documented in the literature, pigmented fibrous lesions with features of both entities are not well described.
  • [MeSH-major] Antigens, CD34 / metabolism. Cell Proliferation. Dermatofibrosarcoma / pathology. Histiocytoma, Benign Fibrous / pathology. Melanocytes / metabolism. Melanocytes / pathology
  • [MeSH-minor] Adult. Dermis / metabolism. Dermis / pathology. Diagnosis, Differential. Female. Humans. Male. Skin Pigmentation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18806495.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


12. Maire G, Fraitag S, Galmiche L, Keslair F, Ebran N, Terrier-Lacombe MJ, de Prost Y, Pedeutour F: A clinical, histologic, and molecular study of 9 cases of congenital dermatofibrosarcoma protuberans. Arch Dermatol; 2007 Feb;143(2):203-10
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinical, histologic, and molecular study of 9 cases of congenital dermatofibrosarcoma protuberans.
  • BACKGROUND: The diagnosis of dermatofibrosarcoma protuberans (DFSP) in childhood is often difficult because of the deceptive appearance of the lesions.
  • Little is known about congenital DFSP, the frequency of which is probably underestimated because the initial lesion may pass unnoticed.
  • OBSERVATIONS: We studied 9 DFSP congenital cases (8 plaques and 1 nodule) initially suspected to be benign lesions.
  • Histologic patterns were similar to the DFSP adult classic pattern in 4 cases.
  • One case was a Bednar tumor.
  • The histologic diagnosis of the 4 remaining cases was difficult.
  • CONCLUSIONS: All cases of congenital DFSP were difficult to identify clinically.
  • The diagnosis was suspected by means of histologic and immunohistochemical evaluation and was confirmed using molecular analyses.
  • This study illustrates the difficulties and pitfalls of the recognition of congenital DFSP and emphasizes the value of immunohistochemical study with anti-CD34 and complementary molecular analysis for all cutaneous spindle cell tumors and plaques in neonates and infants.
  • [MeSH-major] Dermatofibrosarcoma / genetics. Dermatofibrosarcoma / pathology. Oncogene Proteins, Fusion / genetics. Skin Neoplasms / genetics. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17310000.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / COLIA1-PDGFB fusion protein, human; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


13. Patnayak R, Prayaga A, Anuradha S, Ahmed F, Jena A, Gupta V: Pigmented dermatofibrosarcoma protuberance (Bednar tumor). Eur J Dermatol; 2008 Jan-Feb;18(1):98-100
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pigmented dermatofibrosarcoma protuberance (Bednar tumor).
  • [MeSH-major] Dermatofibrosarcoma / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18086613.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] France
  •  go-up   go-down


14. Bisceglia M, Spagnolo D, Galliani C, Fisher C, Suster S, Kazakov DV, Cooper K, Michal M: Tumoral, quasitumoral and pseudotumoral lesions of the superficial and somatic soft tissue: new entities and new variants of old entities recorded during the last 25 years. Part XII: appendix. Pathologica; 2006 Aug;98(4):239-98

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In an eleven part series published in Pathologica, we have presented various tumoral, quasitumoral and pseudotumoral lesions of the superficial and somatic soft tissue (ST), which emerged as new entities or as variants of established entities during the last quarter of a century.
  • Detailed clinicomorphological and differential diagnostic features of approximately sixty entities were chosen on the basis of their clinical significance and morphologic distinctiveness.
  • The series included fibrous and myofibroblastic tumors (e.g. solitary fibrous tumor, high grade classic and pigmented dermatofibrosarcoma protuberans, inflammatory myofibroblastic tumor and myofibrosarcomas), fibromyxoid and fibrohistiocytic neoplasms (e.g., Evans' tumor, phosphaturic mesenchymal tumor, inflammatory myxohyaline tumor), special adipocytic/vascular/and smooth muscle lesions (e.g., chondroid lipoma, Dabska's tumor, ST hemangioblastoma, lipoleiomyosarcoma), epithelioid mesenchymal malignancies of diverse lineages (e.g., epithelioid liposarcoma, proximal-type epithelioid sarcoma, neuroendocrine extraskeletal chondromyxoid sarcoma), ST Ewing's tumor and peripheral nerve sheath tumors (perineuriomas and pigmented and rosetting tumors of the schwannoma/neurofibroma group), extranodal dendritic or histiocytic proliferative processes (follicular dendritic cell sarcoma, Rosai-Dorfman disease, Castleman's disease, and plexiform xanthomatous tumor), and tumors with myoepithelial differentiation.
  • The section devoted to selected pseudotumoral entities considered representatives of the hamartoma group (neural fibrolipomatous hamartoma, ectopic hamartomatous thymoma, rudimentary meningocele), metabolic diseases (amyloid tumor, nephrogenic fibrosing dermopathy, tophaceous pseudogout, pseudoinfiltrative parathyromatosis), stromal tissue reactions to trauma (fibroosseous pseudotumors of digits) and infections (bacillary angiomatosis), and normal organs (glomus coccygeum).
  • To conclude the descriptive phase, supplementary material has now been collected and appended in an attempt to provide a quick digest of essential knowledge both for comparison and differential diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175794.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 272
  •  go-up   go-down


15. Macák J, Zavrelová I: [Melanoma simulating malignant soft tissue tumour]. Cesk Patol; 2005 Oct;41(4):146-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Melanoma simulating malignant soft tissue tumour].
  • The authors presented the case of an 82-year-old man with primary nodular melanoma of the skin on the back (Breslow 3 mm) which repeatedly metastasized five times to the cervical lymph nodes.
  • The aim of this report was to demonstrate changes in the phenotype and immunophenotype during tumour progression.
  • The histological pattern assembled malignant mesenchymal tumour - type malignant fibrous histiocytoma.
  • Differential diagnosis includes neurotropic-desmoplastic malignant melanoma, Bednár tumour (pigmented dermatofibrosarcoma protuberans; storiform neurofibroma), malignant peripheral nerve sheath tumour (neurogenic sarcoma) and malignant fibrous histiocytoma.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / pathology. Melanoma / pathology. Skin Neoplasms / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Microscopy, Electron

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16382990.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


16. Henklova P, Vrzal R, Papouskova B, Bednar P, Jancova P, Anzenbacherova E, Ulrichova J, Maurel P, Pavek P, Dvorak Z: SB203580, a pharmacological inhibitor of p38 MAP kinase transduction pathway activates ERK and JNK MAP kinases in primary cultures of human hepatocytes. Eur J Pharmacol; 2008 Sep 28;593(1-3):16-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the current paper, we studied the effect of SB203580, a pharmacological inhibitor of p38 MAPK, on activation and inhibition of p38 MAPK transduction partway in primary human hepatocytes (in vitro model of differentiated cells) in comparison with several tumor cell lines (proliferating non-differentiated in vitro model).
  • In addition, we analyzed the effect of SB203580 on extracellular-regulated protein kinase (ERK) and c-jun-N-terminal kinase (JNK) pathways both in primary human hepatocytes and tumor cell lines employing primary antibodies detecting phosphorylated kinases.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18655782.001).
  • [ISSN] 0014-2999
  • [Journal-full-title] European journal of pharmacology
  • [ISO-abbreviation] Eur. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Imidazoles; 0 / Pyridines; 0 / SB 203580; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


17. Llombart B, Sanmartín O, López-Guerrero JA, Monteagudo C, Serra C, Requena C, Poveda A, Vistós JL, Almenar S, Llombart-Bosch A, Guillén C: Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1-PDGFB ) study with therapeutic implications. Histopathology; 2009 Jun;54(7):860-72
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1-PDGFB ) study with therapeutic implications.
  • AIMS: To analyse the presence of collagen type I alpha 1-platelet-derived growth factor beta (COL1A1-PDGFB) transcripts in 20 cases of dermatofibrosarcoma protuberans (DFSP) and to assess the relationship between COL1A1 breakpoints and clinical and histopathological variables.
  • Histologically, most cases were of conventional type (n = 9), followed by fibrosarcoma (n = 4), Bednar tumour (n = 2), sclerosing (n = 2), myoid (n = 1) and atrophic (n = 1) DFSP, and giant cell fibroblastoma (n = 1).
  • There was no recurrence of DFSP in any of the 19 patients treated by Mohs surgery.
  • CONCLUSIONS: The COL1A1-PDGFB fusion was present in all histological subtypes of DFSP, but not all cases expressed the fusion transcript.
  • Imatinib mesylate can be useful in locally advanced tumours and metastases.
  • [MeSH-major] Collagen Type I / genetics. Dermatofibrosarcoma / genetics. Dermatofibrosarcoma / pathology. Genes, sis. Skin Neoplasms / genetics. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19635106.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Collagen Type I; 0 / DNA Primers; 0 / Piperazines; 0 / Pyrimidines; 0 / collagen type I, alpha 1 chain; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


18. Bednar W, Holzmann K, Marian B: Assessing 12(S)-lipoxygenase inhibitory activity using colorectal cancer cells overexpressing the enzyme. Food Chem Toxicol; 2007 Mar;45(3):508-14
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To demonstrate the models suitability of 12(S)-LOX overexpressing SW480 cells they were used to measure the inhibitory activity of the plant phenols baicalein, kaempferol, quercetin, nordihydroguaretic acid and resveratrol which are known for their chemopreventive as well as LOX-inhibitory activity in different tumour models.
  • [MeSH-minor] Arachidonate 12-Lipoxygenase / biosynthesis. Arachidonate 12-Lipoxygenase / genetics. Cell Line, Tumor. Colorectal Neoplasms / pathology. Colorectal Neoplasms / prevention & control. DNA Primers. Humans. Polymerase Chain Reaction. RNA / analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17027136.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Lipoxygenase Inhibitors; 0 / Protective Agents; 63231-63-0 / RNA; EC 1.13.11.31 / Arachidonate 12-Lipoxygenase
  •  go-up   go-down


19. Bednar DA, Bednar VA, Chaudhary A, Farrokhyar F: Tranexamic acid for hemostasis in the surgical treatment of metastatic tumors of the spine. Spine (Phila Pa 1976); 2006 Apr 15;31(8):954-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tranexamic acid for hemostasis in the surgical treatment of metastatic tumors of the spine.
  • METHODS: During a 6-month trial period, 14 patients with spine cancer undergoing palliative intralesional tumor excision and concomitant instrumentation to stabilize the spine in the hands of a single surgeon were administered tranexamic acid intraoperatively in the attempt to minimize operative blood loss.
  • Optimum protocol might include routine preoperative angiographic tumor embolization to decrease lesion vascularity in all cases, but angiography is not without risk.
  • Noninvasive prophylaxis of tumor bleeding would have obvious desirable advantages but was, unfortunately, not achieved in this study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Spine. 2006 Jul 15;31(16):1866. Farroukhyar, Forough [corrected to Farrokhyar, Forough]
  • (PMID = 16622388.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6T84R30KC1 / Tranexamic Acid
  •  go-up   go-down


20. Mikolyzk DK, Bednar MS: Merkel cell tumor of the hand: report of two cases. J Hand Surg Am; 2008 Mar;33(3):404-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell tumor of the hand: report of two cases.
  • In this article, we review 2 cases of Merkel cell carcinoma of a digit treated with ray resection and sentinel lymph node dissection with greater than 5 years of follow-up.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18343299.001).
  • [ISSN] 0363-5023
  • [Journal-full-title] The Journal of hand surgery
  • [ISO-abbreviation] J Hand Surg Am
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Kossodo S, Pickarski M, Lin SA, Gleason A, Gaspar R, Buono C, Ho G, Blusztajn A, Cuneo G, Zhang J, Jensen J, Hargreaves R, Coleman P, Hartman G, Rajopadhye M, Duong LT, Sur C, Yared W, Peterson J, Bednar B: Dual in vivo quantification of integrin-targeted and protease-activated agents in cancer using fluorescence molecular tomography (FMT). Mol Imaging Biol; 2010 Oct;12(5):488-99
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Integrins, especially α(v)β(3) and α(v)β(5), are upregulated in tumor cells and activated endothelial cells and as such, serve as cancer biomarkers.
  • PROCEDURES: A small peptidomimetic α(v)β(3) antagonist was synthesized, coupled to a near-infrared fluorescent (NIRF) dye, and tested for binding specificity using integrin-overexpressing cells, inhibition of vitronectin-mediated cell attachment, binding to tumor and endothelial cells in vitro, and competition studies.
  • Pharmacokinetics, biodistribution, specificity of tumor targeting, and the effect of an antiangiogenic treatment were assessed in vivo.
  • RESULTS: The integrin NIRF agent showed strong selectivity towards α(v)β(3/)α(v)β(5) in vitro and predominant tumor distribution in vivo, allowing noninvasive and real-time quantification of integrin signal in tumors.
  • Simultaneous imaging revealed different patterns of distribution reflecting the underlying differences in integrin and cathepsin biology during tumor progression.
  • CONCLUSIONS: NIRF-labeled integrin antagonists allow noninvasive molecular fluorescent imaging and quantification of tumors in vivo, improving and providing more refined approaches for cancer detection and treatment monitoring.
  • [MeSH-minor] Animals. Blotting, Western. Cell Line, Tumor. Female. Fluorescence. Humans. Immunohistochemistry. Mice. Mice, Inbred BALB C. Microscopy, Confocal. Tissue Distribution. Transplantation, Heterologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1994 Apr 22;264(5158):569-71 [7512751.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3056-61 [10955784.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9764-9 [8790405.001]
  • [Cites] Nucl Med Biol. 2006 Apr;33(3):349-58 [16631083.001]
  • [Cites] Nat Rev Cancer. 2002 Feb;2(2):91-100 [12635172.001]
  • [Cites] Nucl Med Biol. 2004 Feb;31(2):179-89 [15013483.001]
  • [Cites] Bioorg Med Chem. 2005 Jun 1;13(11):3763-71 [15863003.001]
  • [Cites] Circulation. 2003 Jan 28;107(3):455-60 [12551871.001]
  • [Cites] Med Phys. 2003 May;30(5):901-11 [12772999.001]
  • [Cites] Nat Med. 1998 May;4(5):623-6 [9585240.001]
  • [Cites] J Biomed Biotechnol. 2002;2(3):124-130 [12488576.001]
  • [Cites] J Clin Oncol. 2008 Dec 1;26(34):5610-7 [18981465.001]
  • [Cites] Curr Pharm Des. 2004;10(13):1439-55 [15134568.001]
  • [Cites] Mol Imaging Biol. 2006 Jul-Aug;8(4):226-36 [16791749.001]
  • [Cites] Nat Biotechnol. 2005 Mar;23(3):313-20 [15765087.001]
  • [Cites] Circulation. 2003 Jul 22;108(3):336-41 [12835208.001]
  • [Cites] Curr Pharm Des. 2008;14(22):2140-58 [18781968.001]
  • [Cites] Oncol Rep. 1998 Nov-Dec;5(6):1349-61 [9769367.001]
  • [Cites] Mol Imaging. 2004 Oct;3(4):343-51 [15802051.001]
  • [Cites] J Nucl Med. 2007 Nov;48(11):1862-70 [17942800.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14205-10 [14612570.001]
  • [Cites] Cell. 2002 Sep 6;110(5):599-11 [12230977.001]
  • [Cites] Front Biosci (Landmark Ed). 2009 Jan 01;14 :887-99 [19273106.001]
  • [Cites] Mol Imaging Biol. 2006 Nov-Dec;8(6):315-23 [17053862.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6146-51 [12414640.001]
  • [Cites] Cancer Res. 1997 Oct 15;57(20):4593-9 [9377574.001]
  • [Cites] Breast Cancer Res. 2006;8(2):R20 [16608535.001]
  • [Cites] J Cell Sci. 2006 Oct 1;119(Pt 19):3901-3 [16988024.001]
  • [Cites] Ann Oncol. 2007 Aug;18(8):1400-7 [17693653.001]
  • [Cites] J Immunol Methods. 1984 Mar 16;67(2):379-88 [6200537.001]
  • [Cites] Bioconjug Chem. 2004 Jan-Feb;15(1):41-9 [14733582.001]
  • [Cites] Mod Pathol. 2001 Nov;14(11):1126-32 [11706074.001]
  • [Cites] Mol Imaging. 2005 Oct-Dec;4(4):439-47 [16285906.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 31;102(22):7976-81 [15911748.001]
  • [Cites] Science. 2002 Apr 5;296(5565):151-5 [11884718.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1781-5 [11280722.001]
  • [Cites] Circulation. 2004 Jul 6;110(1):84-90 [15210600.001]
  • [Cites] Cytometry. 1997 May 1;28(1):58-65 [9136756.001]
  • [Cites] Neoplasia. 2002 May-Jun;4(3):191-4 [11988838.001]
  • [Cites] Radiology. 2007 Mar;242(3):751-8 [17325064.001]
  • [Cites] J Med Chem. 2004 Sep 23;47(20):4829-37 [15369386.001]
  • [Cites] J Cell Biol. 2005 Mar 28;168(7):1109-18 [15795319.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):249-57 [11001068.001]
  • [Cites] Clin Cancer Res. 1998 Nov;4(11):2625-34 [9829725.001]
  • [Cites] Genes Dev. 2003 Mar 1;17(5):545-80 [12629038.001]
  • [Cites] Mol Cancer Ther. 2006 Dec;5(12):3122-9 [17172415.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):8009-14 [15520209.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6330-6 [16024635.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Feb 23;14(4):1049-52 [15013021.001]
  • [Cites] J Biol Chem. 1997 Nov 14;272(46):29380-9 [9361020.001]
  • [Cites] Oncology (Williston Park). 2007 Aug;21(9 Suppl 3):6-12 [17927025.001]
  • [Cites] Bioconjug Chem. 2005 Nov-Dec;16(6):1433-41 [16287239.001]
  • [Cites] J Med Chem. 2006 Oct 5;49(20):6087-93 [17004722.001]
  • [Cites] Circ Res. 2007 Apr 27;100(8):1218-25 [17379832.001]
  • [Cites] Mol Cancer. 2007 Jun 12;6:41 [17565663.001]
  • [Cites] Annu Rev Cell Dev Biol. 1996;12 :697-715 [8970741.001]
  • (PMID = 19960268.001).
  • [ISSN] 1860-2002
  • [Journal-full-title] Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
  • [ISO-abbreviation] Mol Imaging Biol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Integrins; EC 3.4.- / Peptide Hydrolases
  •  go-up   go-down


22. Reimann JD, Fletcher CD: Myxoid dermatofibrosarcoma protuberans: a rare variant analyzed in a series of 23 cases. Am J Surg Pathol; 2007 Sep;31(9):1371-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myxoid dermatofibrosarcoma protuberans: a rare variant analyzed in a series of 23 cases.
  • The myxoid variant of dermatofibrosarcoma protuberans (DFSPs) is uncommon.
  • To better characterize this unusual variant of DFSP, 23 myxoid DFSPs (DFSP with greater than 50% myxoid stroma) were retrieved from the authors' consult files.
  • Tumor size ranged from 1.5 to 11 cm (median 2.8 cm).
  • Grossly, the tumors were white/tan/gray to yellow, firm to gelatinous soft tissue masses.
  • Histologically, tumor stroma ranged from 50 to 100% myxoid (median 80%).
  • All cases displayed honeycomb infiltration of fat and 16 cases showed cellular areas of more typical DFSP.
  • Four tumors contained pigmented dendritic cells (Bednar variant), 1 showed areas of giant cell fibroblastoma and 1 showed progression to fibrosarcomatous DFSP.
  • In summary, these low-grade lesions are clinically similar to typical DFSP, but their unusual morphology is easily confused with a variety of other tumor types.
  • [MeSH-major] Dermatofibrosarcoma / diagnosis. Skin Neoplasms / diagnosis. Stromal Cells / pathology

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721193.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD34; 0 / S100 Proteins
  •  go-up   go-down


23. Lee MS, Kang MJ, Kim MY, Kim HO, Song KY, Park YM: Congenital Bednar tumour (pigmented dermatofibrosarcoma protuberans). J Eur Acad Dermatol Venereol; 2008 Apr;22(4):509-11
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital Bednar tumour (pigmented dermatofibrosarcoma protuberans).
  • [MeSH-major] Buttocks. Dermatofibrosarcoma / congenital. Skin Neoplasms / congenital
  • [MeSH-minor] Child. Diagnosis, Differential. Humans. Infant

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18363923.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  •  go-up   go-down






Advertisement